Werewolf Therapeutics

Werewolf Therapeutics is a U.S.-based biopharmaceutical company developing transformative conditionally activated proinflammatory immune modulating medicines to unleash a powerful attack on cancer. The company's proprietary technology, called indukine™ molecules, are designed to enhance the body's immune response to cancer by selectively activating within the tumor microenvironment, aiming to address the limitations of current immunotherapy approaches.